Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials with a site in Guangzhou

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Recruiting

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

NCT06289062Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation

DrugsCamrelizumab·Nab-paclitaxel·Cisplatin

Tongji Hospital

Phase 2

Guangzhou, Wuhan

2024-05-08

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan

2024-05-08

Recruiting

AMT-116 in Patients with Solid Tumors

NCT06782334Advanced Solid Tumors

DrugAMT-116

Multitude Therapeutics Inc.

Phase 1/2

144

Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou

2024-05-07

Recruiting

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

NCT06300320Chronic Graft Versus Host Disease

DrugRovadicitinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

Hefei, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Xiangyang, Taian, Shanghai

2024-05-07

Recruiting

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06521255DLBCL

DrugsTafasitamab·Lenalidomide·Rituximab·Oxaliplatin

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3

244

Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou

2024-05-07

Not yet open

Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer

NCT06255379Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer

DrugsFuquinitinib·Tegafur Gimeracil Oteracil

Guangzhou University of Traditional Chinese Medicine

Phase 2

Guangzhou

2024-05-06

By invitation

A Prospective, Randomized, Open, Parallel-controlled, Superior-efficacy Clinical Study of Radical Sigmoidectomy for Sigmoid Cancer Versus Radical Sigmoidectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracing Dissection in the Treatment of Sigmoid Cancer

NCT06396806Sigmoid Cancer

Sun Yat-sen University

Not applicable

1,072

Guangzhou

2024-05-06

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

473

Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang

2024-05-03

Recruiting

De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.

NCT06353685De-escalated Radiotherapy; Head and Neck Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

103

Guangzhou

2024-05-01

Recruiting

Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Disorders of Consciousness

NCT07284732Disorders of Consciousness

Zhujiang Hospital

Not applicable

Guangzhou

2024-05-01

Recruiting

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

NCT06397222Hepatocellular Carcinoma Non-resectable

Second Affiliated Hospital of Guangzhou Medical University

Phase 2

Guangzhou

2024-05-01

Recruiting

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

NCT06397235Hepatocellular Carcinoma Non-resectable

DrugHAIC

Second Affiliated Hospital of Guangzhou Medical University

Phase 2

130

Guangzhou

2024-05-01

Not yet open

Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer

NCT05707468Oligometastatic Prostate Carcinoma

DrugAbiraterone

Changhai Hospital

Not applicable

200

Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai

2024-05-01

Not yet open

KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial

NCT06370026Nasopharyngeal Carcinoma

DrugKSD-101

Sun Yat-sen University

Early Phase 1

Guangzhou

2024-05-01

Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

NCT06384352Advanced Solid Tumors

DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

500

Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou

2024-05-01

Recruiting

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

NCT06592417Advanced Malignant Solid Tumor

DrugJSKN016

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1

140

Fuzhou, Guangzhou

2024-04-30

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin

2024-04-29

Recruiting

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugBirelentinib

Dizal Pharmaceuticals

Phase 2

155

Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian

2024-04-29

Recruiting

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385925Malignant Neoplasm

DrugsFluorouracil·Leucovorin·Oxaliplatin

Tyligand Pharmaceuticals (Suzhou) Limited

Phase 1/2

440

Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai

2024-04-29

Recruiting

Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

NCT06685978Hyperplasia of Mammary Glands

Tasly Pharmaceutical Group Co., Ltd

Phase 3

430

Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing

2024-04-26

Recruiting

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

NCT06387069Acute Myeloid Leukemia

DrugHMPL-306

Hutchmed

Phase 3

316

Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou

2024-04-26

Recruiting

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

NCT06298968Intrahepatic Cholangiocarcinoma

Nanfang Hospital, Southern Medical University

Phase 2

Guangzhou

2024-04-26

Active, closed

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008Perennial Allergic Rhinitis (PAR)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

450

Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai

2024-04-26

Recruiting

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor

Qilu Pharmaceutical Co., Ltd.

Phase 1

250

Guangzhou, Harbin, Nanchang, Shanghai, Kunming

2024-04-25

Recruiting

A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB

NCT06781151Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent

Sun Yat-sen University

Observational

200

Guangzhou, Shenzhen

2024-04-24

Active, closed

A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06114511Non-small Cell Lung Cancer

DrugT-Bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1/2

Guangzhou

2024-04-24

Active, closed

Evolve China PMCF Study

NCT06368622Intracranial Aneurysm

Stryker Neurovascular

Observational

500

Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao

2024-04-24

Recruiting

Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure

NCT06904755Liver Failure

Kebo Zhong

Phase 1

Guangzhou

2024-04-23

Recruiting

Cohort Study on Neuroimmune Diseases in the Reproductive Age

NCT07653984Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis, Autoimmune Encephalitis, Myasthenia Gravis

Third Affiliated Hospital, Sun Yat-Sen University

Observational

100

Guangzhou

2024-04-21

Active, closed

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning

2024-04-21

Recruiting

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression

NCT06269211Carcinoma, Non-Small-Cell Lung

DrugToripalimab

Ruijin Hospital

Phase 2

Guangzhou, Shanghai

2024-04-20

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

2024-04-18

Active, closed

Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study

NCT06451302Ewing Sarcoma, Risk Stratification

Yizhuo Zhang

Not applicable

100

Guangzhou

2024-04-17

Active, closed

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

NCT06394414Advanced Solid Tumors

DrugsTam-Peli·Serplulimab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

187

Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin

2024-04-17

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot

2024-04-16

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Beijing, Changchun, Chongqing, Fuzhou, Guangxi, Guangzhou, Guiyang, Ningbo

2024-04-16

Recruiting

Individualized Elective Neck Irradiation in NPC Patients

NCT06241612Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3

470

Guangzhou

2024-04-16

Recruiting

Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma

NCT06364384Rectal Squamous Cell Carcinoma

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2

Guangzhou

2024-04-12

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

Baotou, Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Guangzhou

2024-04-12

Recruiting

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

NCT06233942Advanced Solid Tumor

DrugsTislelizumab·Bevacizumab

BeOne Medicines

Phase 1

308

Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan

2024-04-12

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2024-04-11

Active, closed

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

NCT06251180B-cell Non-Hodgkin Lymphoma

DrugsRocbrutinib·Vincrystine·Adriamycin·Doxorubicin

Guangzhou Lupeng Pharmaceutical Company LTD.

Phase 1

112

Guangzhou

2024-04-10

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Beijing, Cheng Du Shi, Chongqing, Guangzhou, Shenyang, Tianjin, Wenzhou, Wuhan

2024-04-09

Recruiting

Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Reducing Recurrence of Colorectal Adenoma (CRA)

NCT06205862Fecal Microbiota Transplantation, Colorectal Adenoma, Gastrointestinal Microbiome

Shenzhen Hospital of Southern Medical University

Phase 2

466

Guangzhou, Shenzhen, Shunde

2024-04-09

Recruiting

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

NCT06315231Post-stroke Cognitive Impairment

DrugEdaravone dexborneol sublingual

Simcere Pharmaceutical Co., Ltd

Phase 2

226

Fuyang, Hefei, Huangshan City, Guangzhou, Wuzhou, Shijiazhuang, Zhumadian, Nanchang

2024-04-08

Recruiting

Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary

NCT06883487Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian Cancer, Observing the Effectiveness of Targeted HER2 ADC Drugs

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

144

Guangzhou

2024-04-07

Recruiting

Modified Intermittent Eating on Weight Loss (INTEREST-3 Trial)

NCT06302803Obesity

Nanfang Hospital, Southern Medical University

Not applicable

225

Guangzhou

2024-04-07

Recruiting

A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

NCT06319456CLL/SLL

DrugsChlorambucil·Lisaftoclax·Acalabrutinib·Fludarabine

Ascentage Pharma Group Inc.

Phase 3

344

Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin

2024-04-07

Recruiting

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)

NCT06313190Hepatocellular Carcinoma

DrugSintilimab

Sun Yat-sen University

Phase 2

140

Guangzhou

2024-04-05

Active, closed

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132Generalized Epidermolysis Bullosa Simplex

TWi Biotechnology, Inc.

Phase 2/3

Guangzhou

2024-04-04

Recruiting

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

NCT06483347Lung Cancer, Inoperable Disease

DrugsDurvalumab, idarubicin, bevacizumab·Ipilimumab·Pembrolizumab

Second Affiliated Hospital of Guangzhou Medical University

Phase 2

Guangzhou

2024-04-04

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou

2024-04-03

Recruiting

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

NCT06383728Lung Cancer, Carcinoma, Squamous Cell

DrugsTagrisso·Osimertinib

The First Affiliated Hospital of Guangzhou Medical University

Phase 2

Guangzhou

2024-04-01

Not yet open

Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS

NCT06317896Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery

Zhujiang Hospital

Observational

Foshan, Guangzhou

2024-04-01

Active, closed

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

NCT06300424Non Small Cell Lung Cancer, EGFR Gene Mutation

DrugsAlmonertinib·Nab-paclitaxel·Carboplatin

Guangdong Provincial People's Hospital

Phase 2

Guangzhou

2024-04-01

Recruiting

Interventional Software for Multi-immunotherapy of Solid Tumors

NCT06478108Lung Cancer, Liver Cancer, Solid Tumor, Adult

Second Affiliated Hospital of Guangzhou Medical University

Phase 2/3

Guangzhou

2024-04-01

Not yet open

Transfusion in Cardiac Valve Surgery

NCT06332547Cardiac Surgery With Cardiopulmonary Bypass, Valve Heart Disease

Guangdong Provincial People's Hospital

Not applicable

1,600

Guangzhou

2024-04-01

Recruiting

Factors Associated With Posttransplant Cardiac Outcomes

NCT06290154Cardiovascular Diseases, Liver Transplantation

Sun Yat-sen University

Observational

200

Guangzhou

2024-04-01

Recruiting

A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis

NCT06308328Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain

Nanfang Hospital, Southern Medical University

Observational

718

Guangzhou, Shaoguan, Shenzhen, Zhuhai, Shanghai, Chengdu

2024-04-01

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou

2024-03-29

Not yet open

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

NCT06298266Relapsed or Refractory Multiple Myeloma

Guangdong Second Provincial General Hospital

Early Phase 1

Guangzhou

2024-03-29

Recruiting

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

NCT05514015Primary Membranous Nephropathy

DrugRituximab

First Affiliated Hospital, Sun Yat-Sen University

Phase 4

Guangzhou

2024-03-29

Active, closed

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950Ulcerative Colitis

DrugZasocitinib

Takeda

Phase 2

213

Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou

2024-03-29

Recruiting

Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)

NCT06284642Aneurysmal Subarachnoid Hemorrhage

DrugUrokinase

Second Affiliated Hospital of Nanchang University

Phase 4

424

Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha

2024-03-28

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

NCT06300177Non Small Cell Lung Cancer

DrugsD-1553·Docetaxel

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

522

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang

2024-03-28

Recruiting

The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy

NCT06418698Stroke, Acute, Ischemic Stroke, Vascular Diseases, Central Nervous System Diseases

Zhujiang Hospital

Observational

434

Guangzhou

2024-03-28

Active, closed

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

NCT06464991Multiple Myeloma

DrugsEquecabtagene Autoleucel·Pomalidomide·Bortezomib·Daratumumab

Nanjing IASO Biotechnology Co., Ltd.

Phase 3

260

Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang

2024-03-27

Recruiting

A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

NCT06307925Advanced Solid Tumor

DrugHC010

HC Biopharma Inc.

Phase 1

122

Guangzhou

2024-03-27

Recruiting

A Study of CS23546 in Subjects With Advanced Tumors

NCT06245122Advanced Tumors

Chipscreen Biosciences, Ltd.

Phase 1

156

Guangzhou

2024-03-27

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

NCT06323369Head and Neck Squamous Cell Carcinoma

DrugsCarboplatin（adjuvant）·Cisplatin （neoadjuvant）·Cisplatin（adjuvant）·Nab-paclitaxel （neoadjuvant）

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

154

Guangzhou

2024-03-25

Active, closed

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer

Acerand Therapeutics (Shanghai) Limited

Phase 1/2

298

Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan

2024-03-22

Recruiting

TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

NCT06301165Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2

162

Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan

2024-03-19

Recruiting

The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis

NCT06244264Spinal Metastases, Blood Transfusion Complication, Lung Cancer, Surgery

Guangdong Provincial People's Hospital

Not applicable

118

Guangzhou

2024-03-15

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Beijing, Guangzhou, Shanghai

2024-03-12

Active, closed

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer

DrugsBGB-43395·Fulvestrant

BeiGene

Phase 1

103

Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an

2024-03-11

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

NCT06339619Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

DrugsTegafur·Apatinib·Adebrelimab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2024-03-11

Recruiting

Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

NCT06261125Hepatocellular Carcinoma

DrugsAdebrelimab·Lenvatinib

Mian XI

Phase 2

Guangzhou

2024-03-10

Recruiting

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

NCT06055179Xiao Chai Hu Tang, Irinotecan-induced Diarrhea

DrugIrinotecan

Guangzhou University of Traditional Chinese Medicine

Not applicable

Guangzhou

2024-03-08

Recruiting

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT06118788Leukemia, Myeloid, Acute

Guangzhou Bio-gene Technology Co., Ltd

Phase 1/2

Guangzhou, Hangzhou

2024-03-07

Recruiting

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

NCT06277050Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy

Jiangxi Provincial Cancer Hospital

Phase 3

264

Ganzhou, Guangzhou, Nanchang

2024-03-07

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461Crohn's Disease

DrugZasocitinib

Takeda

Phase 2

268

Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou

2024-03-05

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei

2024-03-04

Recruiting

Improvement of Depression With Use of ATP

NCT06266715Depression

Nanfang Hospital, Southern Medical University

Not applicable

120

Guangzhou

2024-03-04

Recruiting

De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma

NCT06313450Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY

Sun Yat-sen University

Not applicable

112

Guangzhou

2024-03-04

By invitation

High-protein Oral Nutrition With HMB for Active CD Patients With Sarcopenia

NCT07171593Handgrip Strength

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

Guangzhou

2024-03-04

Active, closed

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)

NCT06143748Esophagus Cancer

DrugsPaclitaxel and Cisplatin)·Cadonilimab·Taxol

Sun Yat-sen University

Phase 2

Guangzhou

2024-03-02

Recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

NCT06239727Nasopharyngeal Carcinoma

DrugsCamrelizumab·Capecitabine·Gemcitabine·Cisplatin

Sun Yat-sen University

Phase 3

593

Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning

2024-03-01

Recruiting

Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis

NCT06582940MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis

Sun Yat-sen University

Phase 2

168

Guangzhou

2024-03-01

Not yet open

Myeloprotection With Trilaciclib in Pan-cancer Population

NCT06297811Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer

DrugsTrilaciclib·Paclitaxel·Carboplatin

Sun Yat-sen University

Phase 2

132

Guangzhou

2024-03-01

Active, closed

Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference

NCT06321107Infertility

Changchun GeneScience Pharmaceutical Co., Ltd.

Observational

158

Guangzhou

2024-03-01

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

NCT06280508Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2024-03-01

Recruiting

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

NCT06316960AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia

DrugsIdarubicin Hydrochloride·Granulocyte Colony-Stimulating Factor·Avapritinib·Decitabine

Children's Hospital of Soochow University

Phase 2

Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou

2024-03-01

Recruiting

Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China

NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia

Peking University Third Hospital

Observational

2,000

Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin

2024-03-01

Recruiting

A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis

NCT06287788Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain

Nanfang Hospital, Southern Medical University

Observational

240

Guangzhou

2024-03-01

By invitation

Endoscopic Balloon Dilatation Combined With PRP Injection in Colonic Stenosis in Crohn's Disease

NCT06165289Crohn Disease

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

Guangzhou

2024-03-01

Recruiting

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)

NCT06187597Locally Advanced Esophageal Squamous Cell Carcinoma

DrugsTegafur·Teysuno·Toripalimab

Sun Yat-sen University

Phase 2

140

Guangzhou

2024-03-01

Not yet open

Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)

NCT06227286Mitral Regurgitation

Sun Yat-sen University

Not applicable

176

Guangzhou, Jieyang, Shantou, Zhongshan

2024-03-01

Recruiting

Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

NCT06607796Lung Cancer

Zhou Chengzhi

Phase 3

180

Guangzhou

2024-03-01

Not yet open

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

NCT06310473Gastric Cancer, Esophagogastric Junction Cancer

DrugsCadonilimab·Capecitabine·Oxaliplatin

Nanfang Hospital, Southern Medical University

Phase 2

Guangzhou

2024-03

Recruiting

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

NCT06313463Breast Neoplasms

DrugCapecitabine

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

375

Guangzhou

2024-03

Recruiting

Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction

NCT06319157Breast Neoplasms

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

Guangzhou

2024-03

Recruiting

The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery

NCT06425874Breast Cancer, Surgery, Quality of Life

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

1,000

Guangzhou

2024-02-29

Active, closed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118Dermatitis Atopic

DrugsPimecrolimus·Amlitelimab·Tacrolimus

Sanofi

Phase 3

464

Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang

2024-02-29

Active, closed

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081Early Breast Cancer

DrugsLeuprolide·Goserelin·Exemestane·Ribociclib

Novartis Pharmaceuticals

Phase 3

1,466

Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan

2024-02-28

Recruiting

Non-invasive Tools for PSVD Diagnosis

NCT06500403Non-Cirrhotic Portal Hypertension, Porto-Sinusoidal Vascular Diseases

Nanfang Hospital, Southern Medical University

Observational

1,000

Guangzhou

2024-02-28

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Xi’an, Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning

2024-02-27

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

Chengdu, Guangzhou

2024-02-26

Active, closed

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

NCT06271837Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)

DrugsTrastuzumab deruxtecan·Bevacizumab

AstraZeneca

Phase 2

127

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongyang, Guangzhou, Hangzhou

2024-02-22

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

NCT06241846Metastatic Castration-resistant Prostate Cancer (mCRPC)

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2

100

Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan

2024-02-22

Active, closed

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

NCT06244485Advanced Solid Tumor

DrugsValemetostat Tosylate·Dato-DXd·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 1

210

Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong

2024-02-22

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Hefei, Fuzhou, Foshan, Guangzhou, Jiangmen, Nanning, Luoyang, Zhengzhou

2024-02-21

Recruiting

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

NCT06277154Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma

DrugsIfosfamide·Doxorubicin

HRYZ Biotech Co.

Phase 2

148

Guangzhou

2024-02-21

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou

2024-02-20

Active, closed

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

NCT05930275Crohn's Disease

AbbVie

Observational

1,200

Beijing, Chongqing, Guangzhou, Nanjing, Shanghai, Chengdu, Jinhua

2024-02-19

Active, closed

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

NCT06206837Breast Cancer

DrugsVepdegestrant·Atirmociclib

Pfizer

Phase 1/2

Guangzhou, Wuhan, Xi'an

2024-02-19

Recruiting

A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial

NCT06215495Radiation Toxicity, MRI Simulated Positioning, High Grade Glioma, Progression-free Survival

Zhujiang Hospital

Not applicable

Guangzhou

2024-02-18

Recruiting

Endoscopic Stricturotomy Versus Balloon Dilation for Small Bowel Fibrotic Strictures in Crohn's Disease

NCT07833332Crohn Disease (CD), Intestinal Stricture, Intestinal Fibrosis

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

244

Guangzhou

2024-02-18

Recruiting

mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria

NCT06607107Hepatocellular Carcinoma Non-resectable

DrugCamrelizumab and apatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2024-02-17

Active, closed

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140Carcinoma, Non-Small-Cell Lung

DrugsClobetasol·Clindamycin·Chlorhexidine·Minocycline

Janssen Research & Development, LLC

Phase 2

305

Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing

2024-02-16

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou

2024-02-09

Recruiting

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

NCT06112704Advanced Solid Tumor

DrugRis-Rez

Hansoh BioMedical R&D Company

Phase 2

220

Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang

2024-02-06

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou, Wuhan, Changsha

2024-02-05

By invitation

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

NCT06169579Advanced Solid Tumor

Shenzhen NewDEL Biotech, Co., Ltd

Phase 1

Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wu’an

2024-02-04

Recruiting

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

NCT06188624Advanced Cancer

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

150

Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang

2024-02-01

Recruiting

Myasthenia Gravis Registry in China

NCT06241521Myasthenia Gravis

Huashan Hospital

Observational

1,500

Beijing, Chongqing, Guangzhou, Zhengzhou, Changsha, Suzhou, Xuzhou, Nanchang

2024-02-01

Recruiting

A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

NCT06241599Recurrent or Metastatic Nasopharyngeal Carcinoma

DrugCadonilimab

Sun Yat-sen University

Phase 2/3

300

Guangzhou

2024-02-01

Recruiting

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

NCT06280495Colorectal Cancer, Liver Metastases

DrugsSerplulimab·Avastin·Fluorouracil·Adrucil

Sun Yat-sen University

Phase 2/3

156

Guangzhou

2024-02-01

Recruiting

Comparison of Cytokines Profile in Aqueous Humor and Tear Before and After UCP Treatment

NCT06243497Glaucoma, Ultrasound Cyclo Plasty, Aqueous Humor, Tear

Zhongshan Ophthalmic Center, Sun Yat-sen University

Observational

200

Guangzhou

2024-02-01

Recruiting

Immune Dynamics in the Natural History of Chronic HBV Infection

NCT07137247HBV (Hepatitis B Virus), HBV Infection, Chronic Hep B

Nanfang Hospital, Southern Medical University

Observational

5,000

Guangzhou

2024-02-01

Recruiting

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL

NCT06220487Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL, Adult ALL

Nanfang Hospital, Southern Medical University

Phase 2

Guangzhou

2024-02-01

Recruiting

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

NCT07583511Small-cell Lung Cancer

DrugsTeniposide·Serplulimab·Etoposide·Cisplatin

Sun Yat-sen University

Phase 2

Guangzhou

2024-02-01

Recruiting

Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis

NCT06307314Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker

Nanfang Hospital, Southern Medical University

Observational

300

Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou

2024-02-01

Not yet open

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NCT06054191NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation

DrugsCapmatinib·Dabrafenib·Trametinib

Sun Yat-sen University

Phase 2

Guangzhou

2024-02-01

Recruiting

Association Between Genetic Polymorphisms and Type 2 Asthma in Children

NCT06840717Asthma in Children, Genetic Disease, Inflammation

Guangzhou Institute of Respiratory Disease

Observational

300

Guangzhou

2024-01-30

Recruiting

A Multicenter Study Based on Multi-omics Analysis to Predict the Early Prognosis and Recurrence Risk of Acute Ischemic Stroke

NCT06584565Ischemic Stroke, Acute

Nanfang Hospital, Southern Medical University

Observational

400

Guangzhou

2024-01-30

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT05956587Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

DrugsSI-B003·Iza-bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2

121

Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha

2024-01-29

Active, closed

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

NCT06265428HER2-positive Breast Cancer

DrugsDB-1303/BNT323·Trastuzumab emtansine

DualityBio Inc.

Phase 3

228

Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou

2024-01-29

Recruiting

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

NCT06733051Natural Killer T-cell Lymphoma

DrugsGolidocitinib·Benmelstobart

Sun Yat-sen University

Phase 2

Beijing, Guangzhou

2024-01-27

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06244992Locally Advanced or Metastatic Solid Tumors

Pyrotech Therapeutics, Inc.

Phase 1/2

Guangzhou, Beijing

2024-01-26

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245Advanced Solid Tumors, Colorectal Cancer

DrugsVVD-133214·Avastin·Keytruda·Bevacizumab

Vividion Therapeutics, Inc.

Phase 1

280

Hangzhou, Beijing, Guangzhou

2024-01-25

Active, closed

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

NCT06196840Neovascular Age-Related Macular Degeneration

DrugAflibercept

Innostellar Biotherapeutics Co.,Ltd

Phase 2

Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin

2024-01-24

Recruiting

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

NCT06224855Advanced Solid Tumors, Hematological Malignancies

DrugDXC006

Hangzhou DAC Biotechnology Co., Ltd.

Phase 1

280

Hefei, Guangzhou, Changsha, Nanchang, Hangzhou

2024-01-24

Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069SCLC

DrugsZL-1310·Atezolizumab·Carboplatin

Zai Lab (Shanghai) Co., Ltd.

Phase 1

339

Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha

2024-01-23

Recruiting

Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients

NCT06215326Lung Cancer

Guangdong Provincial People's Hospital

Not applicable

100

Guangzhou

2024-01-23

Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)

DrugsAZD3470·Keytruda·Pembrolizumab

AstraZeneca

Phase 1/2

161

Beijing, Guangzhou, Shanghai

2024-01-23

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

NCT06186414Non-Muscle-Invasive Bladder Cancer (NMIBC)

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

152

Beijing, Guangzhou, Haerbin, Zhengzhou, Wuhan, Changsha, Jinan, Qingdao

2024-01-23

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan

2024-01-23

Active, closed

Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

NCT06511726Cervical Cancer

DrugsAlbumin-Bound Paclitaxel /nab-Paclitaxel·Cadonilimab·Cisplatin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2024-01-23

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot

2024-01-22

Active, closed

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

NCT06163326Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

394

Guangzhou, Wuhan, Shenyang, Shanghai, Kunming

2024-01-19

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou

2024-01-18

Recruiting

Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease

NCT06902987Crohn's Diseases, Active Anal Fistula, Upadacitinib

DrugUpadacitinib

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 1

Guangzhou

2024-01-17

Active, closed

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

NCT06144944Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer

DrugEpirubicin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

160

Guangzhou

2024-01-17

Recruiting

Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM

NCT06208371Colorectal Neoplasms Malignant

Sun Yat-sen University

Phase 3

117

Guangzhou

2024-01-15

Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Observational

800

Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou

2024-01-15

Recruiting

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

NCT06268652Breast Cancer, Refractory Breast Carcinoma

DrugsEribulin·Vinorelbine·Xeloda·Capecitabine

Sun Yat-sen University

Phase 3

302

Guangzhou

2024-01-15

Recruiting

PRevention of OsTEoporotiC FracTure 2 Pilot Study

NCT06134908Fragility Fracture

Third Affiliated Hospital, Sun Yat-Sen University

Not applicable

Changsha, Dongguan, Guangzhou, Hangzhou, Hefei, Shenzhen

2024-01-13

Recruiting

Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

NCT06157502Ischemic Stroke, Acute

Beijing Tiantan Hospital

Phase 3

1,380

Beijing, Chongqing, Qianjiang, Guangzhou, Heyuan, Maoming, Meizhou, Yunfu

2024-01-11

Recruiting

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

NCT06219356Non-Hodgkin Lymphoma

Hangzhou GluBio Pharmaceutical Co., Ltd.

Phase 1

110

Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang

2024-01-11

Recruiting

Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)

NCT06220617Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma

Zhejiang University

Observational

3,600

Hangzhou, Guangzhou, Kunming, Nanjing, Xi'an, Zhengzhou

2024-01-11

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,182

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou

2024-01-11

Recruiting

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

NCT06214143Advanced Solid Tumors

DrugT3011

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1/2

Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou

2024-01-11

Recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy

DrugCadonilimab

Sun Yat-sen University

Phase 3

380

Guangzhou, Nanning, Nanchang

2024-01-10

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China

NCT05821855Open-angle Glaucoma, OAG

AbbVie

Phase 4

120

Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Wuhan, Qingdao, Chengdu

2024-01-09

Recruiting

The Effect of Oral Gan Shuangbi During the Perinatal Period on the Recovery of Intestinal Function After Cesarean Section in Pregnant Women- A Multicenter, Double-blind, Randomized Controlled Clinical Trial

NCT06347770Microbiota, Postoperative Recovery

Zhe Li

Phase 1

404

Guangzhou

2024-01-08

Recruiting

A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population

NCT06419413Asthma

AstraZeneca

Observational

355

Chengdu, Beijing, Changsha, Dongguan, Foshan, Guangzhou, Hainan, Hohhot

2024-01-08

Recruiting

ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery

NCT06204835Hepatocellular Carcinoma

Institute of Automation, Chinese Academy of Sciences

Phase 1

Guangzhou, Luzhou

2024-01-07

Recruiting

A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major

NCT06465550β-thalassemia

Shanghai BDgene Co., Ltd.

Phase 1

Guangzhou, Nanning, Shanghai

2024-01-05

Recruiting

A Study of NWY001 in Subjects With Advanced Solid Tumors

NCT05979155Advanced Solid Tumor

Chipscreen Biosciences, Ltd.

Phase 1

196

Guangzhou

2024-01-05

Recruiting

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

NCT06111638Hemophilia A

Shanghai Xinzhi BioMed Co., Ltd.

Phase 2/3

Beijing, Guangzhou, Guiyang, Wuhan, Changsha, Suzhou, Xi’an, Chengde

2024-01-03

Recruiting

Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy

NCT05965531Rectal Cancer

DrugTrifluridine/Tipiracil

Sun Yat-sen University

Phase 2

Guangzhou

2024-01-01

Recruiting

Early Warning and Intervention Mechanism of Foot Health Risk in Children and Adolescents

NCT06581978Flexible Flatfoot

Nanfang Hospital, Southern Medical University

Not applicable

120

Guangzhou

2024-01-01

Recruiting

Exploring the Diagnostic Performance of Dynamic Chest Radiology in Chronic Obstructive Pulmonary Disease

NCT06653413Chronic Obstructive Pulmonary Disease (COPD)

Nanfang Hospital, Southern Medical University

Observational

2,500

Guangzhou

2024-01-01

Recruiting

The Cold Ischemia Robot-assisted Partial Nephrectomy

NCT07326280Renal Cell Carcinoma, Renal Function Abnormal

Sun Yat-sen University

Not applicable

310

Guangzhou

2024-01-01

Active, closed

Rheumatoid Arthritis Real-world Cohort Study in China (ReALSA)

NCT06233929Rheumatoid Arthritis

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

2,000

Guangzhou

2024-01-01

Recruiting

TEER for Severe DMR of Low to Intermediate Surgery Risk

NCT06162780Mitral Regurgitation

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

160

Guangzhou

2024-01-01

Not yet open

China National Study of Adrenal Venous Sampling

NCT06192238Hyperaldosteronism

Chinese Academy of Medical Sciences, Fuwai Hospital

Observational

1,500

Beijing, Chongqing, Xiamen, Lanzhou, Foshan, Guangzhou, Shenzhen, Nanning

2024-01-01

Recruiting

Ultrasound-Guided Curved Needle Thread Carpal Tunnel Release: Efficacy and Safety of a Single-Center, Single-Arm Clinical Trial

NCT06440070Carpal Tunnel Syndrome

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

Guangzhou

2024-01-01

Not yet open

Vitamin D Levels in Neonatal Umbilical Cord Blood: Factors and Prognostic Analysis

NCT06111066Vitamin d Deficiency

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

186

Guangzhou

2024-01-01

Recruiting

Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer

NCT06775977Bladder Cancer, Staging, Contrast Enhanced Ultrasound

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

480

Guangzhou

2024-01-01

Recruiting

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study

NCT07054229Microwave Ablation, Contrast-enhanced Ultrasound, Genetic and Molecular Diagnostics, Papillary Thyroid Microcarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

480

Guangzhou

2024-01-01

Recruiting

SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

NCT06173947End Stage Liver Disease, Jaundice, Liver Dysfunction, Portal Hypertension

Nanfang Hospital, Southern Medical University

Observational

411

Guangzhou

2024-01-01

Recruiting

Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery

NCT06420427cfHPV DNA in Plasma of Cervical Cancer Patients

The Third Affiliated Hospital of Guangzhou Medical University

Observational

150

Guangzhou

2024-01-01

Active, closed

Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: An MRI Study

NCT06881225Nasopharyngeal Carcinoma

Sun Yat-sen University

Observational

300

Guangzhou

2024-01-01

Recruiting

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

NCT06221683AML, Childhood, Acute Myeloid Leukemia

DrugsIdarubicin Hydrochloride·Avapritinib·Mitoxantrone Hydrochloride Liposome·Filgrastim

Children's Hospital of Soochow University

Phase 2

500

Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou

2024-01-01

By invitation

Fetal Magnetic Resonance Imaging: Z-score Reference Ranges for a Large Patient Population in Normal Neuroimaging Measurement

NCT07004283Fetal Growth Retardation, Fetal Neurodevelopmental Disorder

Guangzhou Women and Children's Medical Center

Observational

800

Guangzhou

2024-01-01

Recruiting

Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.

NCT06843707Lung Cancer, Lung, Lung Cancer (NSCLC), Metabolomics

The First Affiliated Hospital of Guangzhou Medical University

Observational

2,500

Guangzhou

2024-01-01

Recruiting

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

NCT06780683Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis

DrugUpadacitinib

Xiang Gao

Observational

174

Guangzhou, Meizhou, Shenzhen, Liuzhou, Nanning

2024-01-01

Recruiting

Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale

NCT07051083Bladder Cancer, Staging, Deep Learning, Neoadjuvant Chemotherapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

480

Guangzhou

2024-01-01

Recruiting

Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases

NCT06541626Multiple Sclerosis, MS, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Acute Disseminated Encephalomyelitis

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

450

Guangzhou

2024-01-01

Not yet open

Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus

NCT06085378Acute Ischemic Stroke, Type 2 Diabetes

DrugUrinary kallidinogenase

First Affiliated Hospital, Sun Yat-Sen University

Not applicable

630

Guangzhou

2024-01-01

Recruiting

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

NCT06197139Advanced Solid Tumor

Drug[177Lu]Lu-XT117

Xinlu Wang

Phase 1

Guangzhou

2024-01

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou

2023-12-31

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha

2023-12-31

Recruiting

Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

NCT05457829Rhabdomyosarcoma, Child

DrugsDoxorubicin Hydrochloride Liposome·Temozolomide·Vincristine·Irinotecan

Sun Yat-sen University

Phase 2

Guangzhou

2023-12-30

Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

NCT05950945Breast Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

250

Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang

2023-12-30

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou

2023-12-29

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Qingdao, Shanghai

2023-12-29

Active, closed

a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection（PROFOUND）

NCT06217900Cancer

Shanghai Weihe Medical Laboratory Co., Ltd.

Observational

16,666

Beijing, Changchun, Guangzhou, Hangzhou, Shenyang

2023-12-28

Recruiting

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

NCT06010329Non-small Cell Lung Cancer

DrugSutetinib Maleate

Teligene US

Phase 2

Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jinan

2023-12-27

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Jiazhuang

2023-12-27

Recruiting

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

NCT06155084Metastatic Castration-resistant Prostate Cancer

Hinova Pharmaceuticals Inc.

Phase 1/2

Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou

2023-12-26

Recruiting

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

NCT06201065Hepatocellular Carcinoma

DrugsToripalimab·Lenvatinib

Sun Yat-sen University

Phase 3

200

Guangzhou

2023-12-26

Recruiting

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

NCT06094556Advanced Solid Tumors

DrugSHR-1826

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

240

Guangzhou

2023-12-25

Recruiting

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

NCT06139575Prostate Cancer

Bivision Pharmaceuticals, Inc.

Phase 1/2

Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi

2023-12-22

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2023-12-21

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou

2023-12-21

Active, closed

Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs

NCT06175637Neurofibroma, Plexiform

AstraZeneca

Observational

409

Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang

2023-12-20

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan

2023-12-20

Recruiting

A Study of TAVO412 in Patients with Cancer (TAVO412)

NCT06761651Cancer

Tavotek Biotherapeutics

Phase 1

Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan

2023-12-20

Recruiting

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

NCT06190301Primary Ocular Adnexal MALT Lymphoma

DrugRituximab

Zhongshan Ophthalmic Center, Sun Yat-sen University

Not applicable

108

Guangzhou

2023-12-20

Recruiting

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

NCT06167694Unresectable or Metastatic Breast Cancer

DrugsDalpiciclib Isethionate·HRS-8080

Shandong Suncadia Medicine Co., Ltd.

Phase 1/2

146

Beijing, Guangzhou

2023-12-20

By invitation

The Construction and Effect Verification of a Deep Learning-based Automated Semantic Segmentation Model for Medical Imaging

NCT06864702Artificial Intelligence (AI), Deep Learning, Laparoscopic Surgery

Zhujiang Hospital

Not applicable

220

Guangzhou

2023-12-20

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin

2023-12-19

Recruiting

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

NCT06082102Relapsed/Refractory Marginal Zone Lymphoma

DrugsOrelabrutinib·Lenalidomide·Rituximab

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3

324

Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian

2023-12-19

Recruiting

Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )

NCT06249308Ovarian Cancer

Fudan University

Observational

168

Guangzhou, Shenyang, Shanghai

2023-12-18

Recruiting

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer

DrugHS-20089

Hansoh BioMedical R&D Company

Phase 2

460

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang

2023-12-18

Recruiting

ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

NCT06007729Head and Neck Squamous Cell Carcinoma

DrugRis-Rez

Hansoh BioMedical R&D Company

Phase 2

170

Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou

2023-12-18

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing

2023-12-18

Recruiting

A Study of YL202 in Selected Patients With Advanced Solid Tumors

NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors

DrugYL202 should be infused

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2

200

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin

2023-12-15

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin

2023-12-15

Active, closed

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06082635Non Small Cell Lung Cancer

DrugsTGRX-326·Crizotinib

Shenzhen TargetRx Co., Ltd.

Phase 3

321

Guangzhou

2023-12-14

Recruiting

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

NCT06433869Malignant Ascites

DrugsRmhTNF-NC·Serplulimab·Bevacizumab

Sun Yat-sen University

Phase 2

Guangzhou

2023-12-14

Recruiting

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

NCT06088030Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations

DrugArsenic Trioxide

Yang Li

Phase 2

Guangzhou

2023-12-13

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Ibrutinib·Acalabrutinib

Merck Sharp & Dohme LLC

Phase 3

1,200

Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou

2023-12-13

Active, closed

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473Multiple Sclerosis

DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab

Sanofi

Phase 3

1,655

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou

2023-12-13

Recruiting

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

NCT06122831Myelofibrosis

DrugRovadicitinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2

Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou

2023-12-12

Recruiting

Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye

NCT07634913Artifical Intelligence, Cataract, Pterygium, Keratopathy

Zhongshan Ophthalmic Center, Sun Yat-sen University

Observational

3,000

Guangzhou

2023-12-12

Recruiting

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

NCT05861895Solid Tumors, Adult

HighField Biopharmaceuticals Corporation

Phase 1

Guangzhou

2023-12-12

Recruiting

PostoperAtive Neurocognitive Dysfunction After Major AbdomiNal Surgery (PANDAMAN)

NCT06182215Elective Major Abdominal Surgery

Sixth Affiliated Hospital, Sun Yat-sen University

Observational

500

Guangzhou

2023-12-11

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin

2023-12-11

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130Advanced Solid Tumor

Eikon Therapeutics

Phase 1/2

156

Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai

2023-12-11

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

110

Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai

2023-12-11

Recruiting

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

NCT06157827Advanced Neuroendocrine Carcinoma

DrugsLBL-024·Etoposide·Atezolizumab·Cisplatin

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

178

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang

2023-12-08

Recruiting

SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx

NCT06219980SBRT

Sun Yat-sen University

Phase 2

Guangzhou

2023-12-07

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, Ürümqi

2023-12-07

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning

2023-12-06

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945Multiple Myeloma

DrugsElranatamab·Pomalidomide·Dexamethasone

AstraZeneca

Phase 1/2

226

Beijing, Changsha, Guangzhou, Shenyang

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Beijing, Changchun, Changsha, Chengdu, Deyang, Fuzhou, Guangzhou, Guiyang

2023-12-04

Active, closed

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

NCT06118333Nasopharyngeal Carcinoma

DrugsIza-bren·Docetaxel·Capecitabine·Gemcitabine

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3

386

Guangzhou

2023-12-04

Recruiting

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

NCT05998759Connective Tissue Diseases, Thrombocytopenia

DrugTelitacicept

Beijing Hospital

Phase 2

296

Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang

2023-12-02

Recruiting

POEM-F for Achalasia International Study

NCT06042127Achalasia

Chinese University of Hong Kong

Not applicable

Guangzhou

2023-12-01

Active, closed

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation

NCT05975307Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy

DrugsJS001·Toripalimab·Gemcitabine·Cisplatin

Sun Yat-sen University

Phase 2

Guangzhou

2023-12-01

By invitation

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

NCT06281964Non-Small-Cell Lung Cancer

DrugsAndamertinib·Pemetrexed·Carboplatin

Avistone Biotechnology Co., Ltd.

Phase 3

327

Guangzhou

2023-12-01

Recruiting

Biometric Changes After Intervention of Anterior Chamber Angle : an Observational Study

NCT06492538Angle-closure Glaucoma, Minimally Invasive Glaucoma Surgery, Goniosynechialysis, Goniotomy

Zhongshan Ophthalmic Center, Sun Yat-sen University

Observational

300

Guangzhou

2023-12-01

Recruiting

Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels

NCT07353216Multiple Sclerosis

DrugOfatumumab

Third Affiliated Hospital, Sun Yat-Sen University

Observational

Guangzhou

2023-12-01

Active, closed

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

NCT06194825Transthyretin Amyloid Cardiomyopathy

DrugEplontersen

AstraZeneca

Phase 3

Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Ha’erbin, Jinan

2023-12-01

Active, closed

Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope

NCT06710873CIED Infection, TYRX Absorbable Antibacterial Envelope

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

Guangzhou

2023-12-01

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer

DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant

BeOne Medicines

Phase 1

433

Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai

2023-12-01

Recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

NCT06079983Breast Cancer

DrugsJSKN003·Eribulin·Vinorelbine·Docetaxel

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

400

Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha

2023-12-01

Recruiting

Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures

NCT06379243Osteoporosis Fracture, Osteoporosis Vertebral, Compression Fracture, Perform PVP / PKP Treatment

The Seventh Affiliated Hospital of Sun Yat-sen University

Not applicable

560

Guangzhou

2023-12-01

Recruiting

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers

DrugXNW28012

Evopoint Biosciences Inc.

Phase 1/2

350

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin

2023-12-01

Recruiting

EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF

NCT06161987Acute Decompensated Heart Failure

Guangdong Provincial People's Hospital

Not applicable

140

Guangzhou

2023-12-01

Recruiting

Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma

NCT06876688CNS Lymphoma

Ruijin Hospital

Phase 2

Beijing, Guangzhou, Henan, Shanghai, Wuhan

2023-11-30

Active, closed

Chronic Kidney Disease Registry Platform Study

NCT06117852Chronic Kidney Diseases

AstraZeneca

Observational

5,000

Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou

2023-11-28

Recruiting

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

NCT05737303Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV

DrugsNab-paclitaxel·Carboplatin

Women's Hospital School Of Medicine Zhejiang University

Phase 3

538

Guangzhou, Ji'nan, Hangzhou, Ningbo, Wenzhou

2023-11-27

Recruiting

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

NCT06155383Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsJS001·Disitamab Vedotin·Toripalimab·Capecitabine

RemeGen Co., Ltd.

Phase 2

Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou

2023-11-27

Active, closed

Guangzhou Preterm and Term Birth Cohort Study

NCT07756177Preterm Birth, Neurodevelopmental Disorders, Overweight, Obesity

Sun Yat-sen University

Observational

200

Guangzhou

2023-11-21

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin

2023-11-21

Recruiting

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

NCT06157060Hepatocellular Carcinoma Resectable

Zhujiang Hospital

Observational

255

Foshan, Guangzhou, Shaoguan

2023-11-20

Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma

DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

914

Guangzhou, Jinan, Shanghai

2023-11-20

Active, closed

Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

NCT06057571Cholangiocarcinoma Metastatic

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 2

Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou

2023-11-17

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsSotorasib·Pembrolizumab

Amgen

Phase 3

750

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou

2023-11-16

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

289

Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi

2023-11-15

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin

2023-11-14

Recruiting

A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

NCT06145893Behçet's Disease

DrugMufemilast

Ganzhou Hemay Pharmaceutical Co., Ltd

Phase 3

162

Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang

2023-11-13

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin

2023-11-13

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin

2023-11-12

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang

2023-11-11

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou

2023-11-09

Recruiting

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

NCT05959356Metastatic Colorectal Cancer

DrugsMFOLFOXIRI·Envafolimab·MFOLFOX6·Cetuximab

Sun Yat-sen University

Phase 2

198

Foshan, Guangzhou, Guiyang

2023-11-09

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin

2023-11-08

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha

2023-11-08

Recruiting

A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i

NCT05953350Inhibition of Autophagy Synergizes Anti-tumor Effect

DrugHydroxychloroquine

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2

Guangzhou

2023-11-07

Active, closed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779Heart Failure

DrugBMS-986435

Bristol-Myers Squibb

Phase 2

227

Beijing, Guangzhou, Luoyang, Changsha, Hangzhou

2023-11-07

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Baotou, Beijing, Changsha, Chengdu, Chongqing, Deyang, Foshan, Guangzhou

2023-11-07

By invitation

Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer

NCT07112209Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer

Zhujiang Hospital

Not applicable

Guangzhou

2023-11-06

Active, closed

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma

DrugsRelmacabtagene Autoleucel·Relma-cel·Fludarabine·Cyclophosphamide

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2

Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou

2023-11-03

Recruiting

Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia

NCT06137196AIDS, Pneumonia

Guangzhou 8th People's Hospital

Observational

100

Guangzhou

2023-11-01

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

NCT06121557Breast Neoplasms

DrugsTumor-draining lymph node-derived lymphocyte·Aldesleukin·Camrelizumab·Fludarabine

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1

Guangzhou

2023-11-01

Recruiting

TDCS Interventions for Subthreshold Depressive Symptoms in Young Individuals.

NCT06294184Subthreshold Depression, Young People, Transcranial Direct Current Stimulation

Guangzhou Psychiatric Hospital

Not applicable

150

Guangzhou

2023-11-01

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

NCT06121570Breast Neoplasms

DrugsTumor-draining lymph node-derived lymphocyte·Aldesleukin·Epirubicin·Doxorubicin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1

Guangzhou

2023-11-01

Recruiting

Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma

NCT06688760Nasopharyngeal Carcinoma, Surgery, Radiotherapy

Ming-Yuan Chen

Not applicable

Guangzhou, Zhuhai

2023-11-01

Recruiting

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

NCT06095596Ulcerative Colitis (UC)

DrugsVedolizumab·Upadacitinib

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

334

Guangzhou

2023-11-01

Recruiting

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

NCT06154538Locally Advanced Colorectal Carcinoma

DrugFolfox

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

170

Beijing, Guangzhou, Jinan

2023-11-01

Recruiting

Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma

NCT06017895Swallowing-induced Pain

Nanfang Hospital, Southern Medical University

Not applicable

178

Guangzhou

2023-10-31

Recruiting

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC

NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity

Sun Yat-sen University

Phase 3

540

Guangzhou

2023-10-31

Recruiting

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

NCT06008288KRAS P.G12C, Pancreatic Cancer, Solid Tumor

DrugGlecirasib

Allist Pharmaceuticals, Inc.

Phase 2

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2023-10-27

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang

2023-10-27

Active, closed

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Yangzhou, Tongzhou, Fuzhou, Lanzhou, Guangzhou, Nanning, Haikou, Shijiazhuang

2023-10-26

Recruiting

A Study of Chidamide With AZA in MRD Positive AML After Transplant

NCT06066905AML, Adult, Minimal Residual Disease

Guangdong Provincial People's Hospital

Not applicable

Guangzhou

2023-10-26

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou

2023-10-25

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang

2023-10-25

Recruiting

Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension

NCT07604805Idiopathic Pulmonary Hypertension

Guangdong Provincial People's Hospital

Not applicable

120

Guangzhou

2023-10-25

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2023-10-24

Active, closed

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

114

Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai

2023-10-23

Recruiting

Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock

NCT06145828AIDS Pneumonia, Septic Shock

Guangzhou 8th People's Hospital

Observational

Guangzhou

2023-10-23

Recruiting

Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies

NCT06145841AIDS, Pneumonia, Sepsis, Neonatal

Guangzhou 8th People's Hospital

Observational

400

Guangzhou

2023-10-23

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai

2023-10-22

Recruiting

A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

NCT06049290Relapsed/Refractory Multiple Myeloma

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

342

Wuhu, Beijing, Xiamen, Guangzhou, Shenzhen, Guiyang, Haikou, Luoyang

2023-10-20

Not yet open

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

NCT06063070Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal Cancer

DrugsFluzoparib·Bevacizumab

Sun Yat-sen University

Phase 2

Guangzhou

2023-10-18

Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

NCT05944224Advanced Solid Tumors

DrugsSPH4336·Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1/2

Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xi’an

2023-10-17

Recruiting

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

NCT05989542Non-small Cell Lung Cancer

DrugVebreltinib

Beijing Pearl Biotechnology Limited Liability Company

Phase 3

136

Guangzhou

2023-10-16

Active, closed

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT06022861Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Opdivo·Cisplatin

Shandong Boan Biotechnology Co., Ltd

Phase 3

510

Guangzhou

2023-10-12

By invitation

A Prospective, Multicenter, Post-marketing Clinical Follow-up Research to Evaluate the Long-term Safety of Ellansé-S Dermal Filler Made of PCL Microspheres for the Correction of Moderate-to-severe Nasolabial Folds

NCT06243315Moderate-to-severe Nasolabial Folds (3-4 Level of WSRS Scores) on Both Sides of the Face

AQTIS Medical B.V.

Observational

374

Guangzhou

2023-10-12

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Beijing, Chongqing, Guangzhou, Shenzhen, Wuhan, Nanchang, Changchun, Xi'an

2023-10-11

Recruiting

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037Lung Transplant Rejection

DrugsBelumosudil·Azithromycin

Sanofi

Phase 3

180

Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi

2023-10-10

Recruiting

A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

NCT06038058Advanced Malignancies

BioRay Pharmaceutical Co., Ltd.

Phase 1

164

Guangzhou

2023-10-10

Recruiting

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

NCT06092957Nasopharyngeal Carcinoma, De-escalation Therapy

Sun Yat-sen University

Phase 3

504

Guangzhou

2023-10-09

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugsEnlicitide Decanoate·Enlicitide

Merck Sharp & Dohme LLC

Phase 3

14,550

Hefei, Beijing, Chongqing, Foshan, Guangzhou, Huizhou, Jiangmen, Shenzhen

2023-10-09

Active, closed

Preoperative Evaluation of 3D Reconstruction Tool for Nipple-sparing Mastectomy

NCT06071234Breast Cancer

Guangdong Provincial People's Hospital

Not applicable

126

Guangzhou

2023-10-08

Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402Multiple Myeloma

DrugElranatamab

Pfizer

Phase 4

Beijing, Guangzhou, Jinan, Hangzhou

2023-10-03

By invitation

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 3

306

Beijing, Shenzhen, Dongguan, Guangzhou, Changsha, Nanjing, Shanghai, Kunming

2023-10-03

Recruiting

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

NCT06327178Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC

Nanfang Hospital, Southern Medical University

Observational

Guangzhou

2023-10-01

Recruiting

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

NCT05949931Classic Hodgkin Lymphoma

Sun Yat-sen University

Phase 2

108

Guangzhou

2023-10-01

Recruiting

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

NCT06088004Solid Tumor, Adult

DrugToripalimab

Suzhou Abogen Biosciences Co., Ltd.

Phase 1/2

218

Beijing, Guangzhou, Nanning, Shanxi, Shenzhen

2023-09-28

Recruiting

Evaluation of Phacogoniotomy in Medically-controlled POAG

NCT06201455Glaucoma, Open-Angle, Cataract Complicated, Goniotomy

Sun Yat-sen University

Not applicable

100

Guangzhou

2023-09-28

Recruiting

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

NCT05997602Langerhans Cell Histiocytosis, LCH

DrugLuvometinib

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2

Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou

2023-09-28

Active, closed

A Study of ADRX-0706 in Select Advanced Solid Tumors

NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer

Adcentrx Therapeutics

Phase 1

144

Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan

2023-09-26

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

Beijing, Changde, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou

2023-09-22

Active, closed

A Study YL201 in Patients With Selected Advanced Solid Tumors

NCT06057922Advanced Solid Tumor

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

990

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou

2023-09-22

Recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

NCT05978648Breast Neoplasms

DrugsTrilaciclib·Epirubicin·Pertuzumab·Trastuzumab

wang shusen

Phase 2

116

Guangzhou

2023-09-20

Recruiting

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

NCT05872347Breast Cancer Brain Metastases

DrugSPH4336

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 2

Hefei, Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Xiangyang

2023-09-19

Recruiting

Recurrent High Grade Glioma Treated by LITT

NCT06161610Recurrent High Grade Glioma

Beijing Tiantan Hospital

Not applicable

135

Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai

2023-09-19

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangdong Province Guangzhou City, Guangzhou

2023-09-18

Recruiting

Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery

NCT06286150Lung Cancer

The First Affiliated Hospital of Guangzhou Medical University

Not applicable

Guangzhou

2023-09-15

Recruiting

A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

NCT06016062Solid Tumor

DrugRC148

RemeGen Co., Ltd.

Phase 1/2

221

Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2023-09-14

Active, closed

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886Hepatocellular Carcinoma

DrugsTiragolumab·Tecentriq·Avastin·Atezolizumab

Hoffmann-La Roche

Phase 3

687

Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou

2023-09-14

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Hefei, Beijing, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi

2023-09-14

Active, closed

Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

NCT07054632Inherited Retinal Dystrophy Associated With RPE65 Mutations

Innostellar Biotherapeutics Co.,Ltd

Phase 3

Guangzhou, Chongqing, Shanghai, Tianjin

2023-09-13

By invitation

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis

DrugEfgartigimod PH20

argenx

Phase 3

240

Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou

2023-09-12

Recruiting

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

NCT06064812Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer

DrugFWD1802

Forward Pharmaceuticals Co., Ltd.

Phase 1/2

Hefei, Guangzhou, Huizhou, Nanning, Luoyang, Xinxiang, Zhengzhou, Wuhan

2023-09-12

Recruiting

Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery

NCT06030804Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors

DrugDexmedetomidine

Peking University First Hospital

Not applicable

4,532

Hefei, Beijing, Chongqing, Fuzhou, Jinjiang, Guangzhou, Shenzhen, Nanning

2023-09-12

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Changsha, Hohhot

2023-09-11

Recruiting

AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

NCT06035250Gastric Cancer, Image, Pathology

Chinese Academy of Sciences

Observational

200

Beijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai

2023-09-10

Recruiting

Detection of Sepsis Occurrence by Using Blood Fluorescence

NCT06745115Sepsis

Zhujiang Hospital

Observational

Guangzhou

2023-09-09

Recruiting

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

NCT05860465Locally Advanced or Metastatic Breast Cancer

DrugSPH4336

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 2/3

254

Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Wuhan, Nanjing

2023-09-08

Active, closed

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

NCT05979961Nasopharyngeal Carcinoma

DrugGemcitabine and cisplatin

Sun Yat-sen University

Phase 3

464

Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha

2023-09-07

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei

2023-09-07

Recruiting

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

NCT06278870HER2-positive Metastatic Breast Cancer, First-line Treatment

DrugsPyrotinib·Disitamab Vedotin·Pertuzumab·Trastuzumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

312

Guangzhou

2023-09-06

Not yet open

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

NCT06016413Head and Neck Squamous Cell Carcinoma

DrugsNab-paclitaxel·Carboplatin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2023-09-01

Active, closed

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05807880Nasopharyngeal Neoplasms

Sun Yat-sen University

Phase 2

Guangzhou

2023-09-01

Recruiting

Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions

NCT05942430Articular Cartilage Defect

The Third Affiliated Hospital of Southern Medical University

Not applicable

Guangzhou

2023-09-01

Recruiting

Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients

NCT06043999Chemotherapy Effect, Rectal Cancer

Sun Yat-sen University

Not applicable

392

Guangzhou

2023-09-01

Active, closed

Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer

NCT05953662Colorectal Neoplasm

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

500

Guangzhou

2023-09-01

Recruiting

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

NCT05954897Hepatocellular Carcinoma

Guangdong Provincial People's Hospital

Phase 2

Guangzhou

2023-09-01

Recruiting

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

NCT06031285Hepatocellular Carcinoma

DrugSintilimab

Sun Yat-sen University

Phase 2

Guangzhou

2023-09-01

Not yet open

Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer

NCT05730595Colorectal Neoplasms, Fluorescence, Lymph Node Excision

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not applicable

550

Hefei, Beijing, Chengdu, Fuzhou, Guangzhou, Shijiazhuang, Haerbin, Nanjing

2023-09-01

Recruiting

Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)

NCT06130332Oral Cancer, PD-1

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2023-09-01

Active, closed

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398Metastatic Castrate-sensitive Prostate Cancer

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

420

Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan

2023-08-31

Active, closed

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

NCT06020885Esophageal Squamous Cell Carcinoma

Sun Yat-sen University

Phase 1

Guangzhou

2023-08-31

Recruiting

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

NCT05908695Alzheimer's Disease

DrugSodium Oligomannate

Green Valley (Shanghai) Pharmaceuticals Co., Ltd.

Phase 4

1,312

Huainan, Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Shijiazhuang, Tangshan

2023-08-31

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an

2023-08-31

Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD

Alexion Pharmaceuticals, Inc.

Observational

200

Beijing, Guangzhou, Henan, Shanghai, Sichuan, Wuhan

2023-08-30

Recruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

NCT05984511Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus

DrugsAtezolizumab·Bevacizumab

Third Affiliated Hospital, Sun Yat-Sen University

Not applicable

234

Guangzhou

2023-08-30

Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

NCT06126224Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

500

Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai

2023-08-28

Active, closed

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

NCT05954910Diffuse Large B-Cell Lymphoma

DrugPolatuzumab Vedotin

Hoffmann-La Roche

Observational

1,000

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Haikou, Hohhot

2023-08-25

Recruiting

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

NCT05962502Metastatic Colorectal Cancer

DrugErbitux

Sun Yat-sen University

Phase 2

Guangzhou

2023-08-24

Recruiting

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

NCT06975618PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM)

DrugCYH33

Haihe Biopharma Co., Ltd.

Phase 1/2

141

Beijing, Fuzhou, Guangzhou, Zhengzhou, Changsha, Shanghai, Chengdu

2023-08-22

Active, closed

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

NCT05995964Atopic Dermatitis

DrugTilrekimig

Pfizer

Phase 2

507

Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanchang

2023-08-22

Recruiting

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

NCT05360277Metastatic Colorectal Cancer，NED

DrugsTislelizumab·Capecitabine

Yanhong Deng

Phase 2

Guangzhou

2023-08-22

Active, closed

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

NCT06174402Primary Biliary Cholangitis

DrugsFenofibrate·UDCA

Han Ying

Phase 2/3

184

Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Yan’an, Kunming, Beijing

2023-08-21

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934ATTR Amyloidosis

AstraZeneca

Observational

52,121

Beijing, Changsha, Chengdu, Guangzhou, Wuhan

2023-08-21

Recruiting

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

NCT06092086ALK Positive Non-small Cell Lung Cancer

DrugLorlatinib

Guangdong Association of Clinical Trials

Phase 2

126

Guangzhou

2023-08-18

Active, closed

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

NCT04586660Giant Cell Tumor of Bone

DrugsXgeva·Denosumab

Amgen

Phase 4

Beijing, Fuzhou, Guangzhou, Harbin, Xi'an, Hangzhou

2023-08-17

Recruiting

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

NCT05914116Advanced Solid Tumors

DrugsBNT324·Abiraterone·Itraconazole·Enzalutamide

DualityBio Inc.

Phase 1/2

862

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin

2023-08-17

Active, closed

Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

NCT06577792Non Small Cell Lung Cancer

Sun Yat-sen University

Not applicable

620

Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing

2023-08-16

Active, closed

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

NCT05949944Peripheral T-cell Lymphoma

DrugsLinperlisib·CHOP

Sun Yat-sen University

Phase 1/2

Guangzhou

2023-08-15

Active, closed

A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

NCT05945901Colorectal Cancer

DrugHR070803

Jiangsu HengRui Medicine Co., Ltd.

Phase 2/3

669

Guangzhou

2023-08-14

Recruiting

SIRT for Potentially Resectable HCC

NCT05994859Hepatocellular Carcinoma

Second Affiliated Hospital of Guangzhou Medical University

Not applicable

Guangzhou

2023-08-10

Active, closed

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

NCT05909397Breast Cancer

DrugsVepdegestrant·Letrozole

Pfizer

Phase 3

Beijing, Guangzhou, Wuhan, Xi'an

2023-08-09

Active, closed

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications

Sun Yat-sen University

Phase 3

474

Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou

2023-08-08

Active, closed

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610Primary IgA Nephropathy

Hoffmann-La Roche

Phase 3

459

Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou

2023-08-08

Recruiting

Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer

NCT05943444Rectal Neoplasms, Low Anterior Resection Syndrome, Anastomotic Leak, Quality of Life

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

256

Guangzhou

2023-08-08

Active, closed

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

NCT05896124Primary Biliary Cholangitis (PBC)

DrugPleacbo

Cascade Pharmaceuticals, Inc

Phase 2

Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Zhenjiang, Changchun

2023-08-07

Active, closed

Microsurgical Resection Combined With Photodynamic Therapy for Recurrent Glioblastoma

NCT07832448Recurrent Glioblastoma (WHO-Grade IV Glioma)

DrugHematoporphyrin

Yonggao Mou

Not applicable

Guangzhou

2023-08-04

Recruiting

Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD

NCT05921305Acute Graft Versus Host Disease

Peking University People's Hospital

Phase 3

218

Beijing, Guangzhou

2023-08-03

Recruiting

Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

NCT05988879AIDS, Hepatitis B

DrugPeginterferon alfa-2b

Guangzhou 8th People's Hospital

Observational

Guangzhou

2023-08-02

Active, closed

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

NCT07003191Type 2 Diabetes

DrugCombination

Sun Yat-sen University

Observational

2,600

Guangzhou

2023-08-02

Recruiting

Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

NCT06101888Aortic Regurgitation

Peijia Medical Technology (Suzhou) Co., Ltd.

Not applicable

116

Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha

2023-08-01

Recruiting

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

NCT05985798Hepatocellular Carcinoma Non-resectable

Second Affiliated Hospital of Guangzhou Medical University

Phase 3

258

Guangzhou

2023-08-01

Active, closed

Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)

NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer

DrugsCadonilimab·Gemcitabine·Cisplatin

Sun Yat-sen University

Phase 3

490

Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning

2023-08-01

Active, closed

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

NCT06044350Optic Neuromyelitis Spectrum Disease

DrugBAT4406F

Bio-Thera Solutions

Phase 2

162

Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou

2023-08-01

Recruiting

Utilization of Transanal Endoscopy in the Treatment of Anastomotic Stenosis

NCT06036862Anastomotic Stenosis

Sun Yat-sen University

Not applicable

Guangzhou

2023-08-01

Recruiting

The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center

NCT06383858Preeclampsia, Maternal Deaths

The Third Affiliated Hospital of Guangzhou Medical University

Observational

50,000

Guangzhou

2023-08-01

Recruiting

Early Diagnosis and Prediction of Maternal and Neonatal Diseases:

NCT06791343Pregnancy-Related and Neonatal Disorders

The Eye Hospital of Wenzhou Medical University

Observational

1,000,000

Guangzhou, Wenzhou

2023-08-01

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200Colonic Neoplasms, Neoplasms, Colon

DrugsCapeox·Dostarlimab·Folfox

GlaxoSmithKline

Phase 3

892

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin

2023-08-01

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

NCT05981001Breast Neoplasms

DrugsTumor-draining lymph node-derived lymphocyte·Aldesleukin·Camrelizumab·Fludarabine

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2

170

Guangzhou

2023-08-01

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

NCT05981014Breast Neoplasms

DrugsTumor-draining lymph node-derived lymphocyte·Aldesleukin·Epirubicin·Doxorubicin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2

196

Guangzhou

2023-08-01

Active, closed

The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens

NCT05886348Myopia

HOYA Lens Thailand LTD.

Not applicable

249

Beijing, Guangzhou, Shanghai, Shengyang, Tianjin

2023-07-31

Recruiting

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

NCT05777278Non-small Cell Lung Cancer

DrugsSavolitinib·Docetaxel

The First Affiliated Hospital of Guangzhou Medical University

Phase 1/2

Guangzhou

2023-07-26

Recruiting

MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer

NCT06204484Colorectal Cancer

Sun Yat-sen University

Not applicable

349

Guangzhou

2023-07-26

Active, closed

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643Systemic Lupus Erythematosus

DrugUpadacitinib

AbbVie

Phase 3

1,014

Bengbu, Beijing, Xiamen, Guangzhou, Shantou, Nanning, Luoyang, Wuhan

2023-07-25

Active, closed

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

NCT06015503NSCLC (Non-small Cell Lung Cancer)

DrugAndamertinib

Avistone Biotechnology Co., Ltd.

Phase 2

139

Guangzhou

2023-07-21

Active, closed

Effects of Shanyu Pill in Older Adults With Sarcopenia

NCT05919368Sarcopenia

Fujian University of Traditional Chinese Medicine

Not applicable

192

Fuzhou, Guangzhou

2023-07-17

Active, closed

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

NCT05943795Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung

DrugsSI-B001·Docetaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3

589

Guangzhou, Hangzhou

2023-07-14

Recruiting

Pulmonary Hypertension Observational Study

NCT05958901Pulmonary Hypertension

The First Affiliated Hospital of Guangzhou Medical University

Observational

10,000

Guangzhou

2023-07-12

Recruiting

A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC

NCT07133958Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)

Zhujiang Hospital

Observational

Guangzhou

2023-07-11

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Nanchang

2023-07-11

Active, closed

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

100

Guangzhou, Chengdu, Beijing

2023-07-11

Recruiting

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

NCT05886920Advanced Solid Tumors With MAPK Pathway Mutations

DrugD3S-001

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou

2023-07-10

Recruiting

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer

NCT05571644Colorectal Cancer

DrugsMFOLFOXIRI·MFOLFOX6·Fruquintinib·Cadonilimab

Sun Yat-sen University

Phase 2

143

Guangzhou

2023-07-10

Recruiting

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

NCT06208917Pediatric Solid Tumor, Unspecified, Protocol Specific

DrugDexamethasone

Yizhuo Zhang

Phase 3

376

Guangzhou

2023-07-09

Active, closed

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

NCT05957510Small-cell Lung Cancer

DrugsSerplulimab·Etoposide·Carboplatin

Guangdong Association of Clinical Trials

Phase 2

Guangzhou

2023-07-07

Active, closed

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

NCT06175351Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Drug9MW1911

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2

Baotou, Beijing, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou, Hengyang

2023-07-06

Active, closed

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy

DrugZigakibart

Novartis Pharmaceuticals

Phase 3

383

Hefei, Beijing, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan

2023-07-06

Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement

DrugFutibatinib

Taiho Oncology, Inc.

Phase 2

120

Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou

2023-07-05

Recruiting

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

NCT05623267Limited Stage Small Cell Lung Cancer

DrugSugemalimab

Sun Yat-sen University

Phase 2/3

346

Guangzhou

2023-07-01

Recruiting

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

NCT06172205BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect

DrugCamrelizumab and apatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

262

Guangzhou

2023-07-01

Recruiting

AI-Driven Genotype Prediction Using EHR and Multimodal Data

NCT06791421Genotype

The Eye Hospital of Wenzhou Medical University

Observational

100,000

Guangzhou, Wenzhou

2023-07-01

Recruiting

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

NCT05904964HR Positive/HER2 Low Expression Metastatic Breast Cancer

DrugDisitamab Vedotin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

288

Guangzhou, Shantou, Qionghai

2023-07-01

Recruiting

PaCIFiC-CUP Classifies Cancer of Unknown Primary

NCT06140992Unknown Primary Tumors, DNA Methylation

Sun Yat-sen University

Observational

120

Guangzhou

2023-07-01

Recruiting

AI-Agent for Automated Diagnosis and Predicting Using EHR and Multimodal Data

NCT06791499AI Agent

The Eye Hospital of Wenzhou Medical University

Observational

2,000,000

Guangzhou, Chengdu, Wenzhou

2023-07-01

Not yet open

Association of Osmotic Drugs With Clinical Outcomes in Acute Large Hemispheric Infarction

NCT05914272Stroke

Nanfang Hospital, Southern Medical University

Observational

2,592

Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang

2023-07-01

Not yet open

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke

NCT05910125Ischemic Stroke

DrugsAlteplase·Clopidogrel·Aspirin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 4

472

Guangzhou

2023-07

Recruiting

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

NCT05894018Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors

DrugFluzoparib

Fujun Zhang

Phase 2

Guangzhou

2023-06-29

Recruiting

Long-term Success Rate of Transvaginal Mesh for the Treatment of Pelvic Organ Prolapse: The Extended RCT Study

NCT05938881Pelvic Organ Prolapse

Peking Union Medical College Hospital

Observational

336

Foshan, Guangzhou, Changsha, Wuxi, Jinan, Xi’an, Chengdu, Ürümqi

2023-06-29

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou

2023-06-28

Active, closed

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

DrugsIrinotecan·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

123

Beijing, Guangzhou

2023-06-27

Active, closed

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

NCT05756972NSCLC

DrugsPumitamig·Pemetrexed·Carboplatin

Biotheus Inc.

Phase 2

Guangzhou

2023-06-26

Active, closed

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

NCT05870319Non-small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Cisplatin·Carboplatin

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

376

Guangzhou

2023-06-26

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing

2023-06-22

Recruiting

Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation

NCT05475613Liver Transplantation, Hepatocellular Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2023-06-21

Active, closed

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

NCT05913037Neurofibromatosis 1, Plexiform Neurofibroma, NF1

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3

167

Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu

2023-06-20

Recruiting

A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities

NCT07394374Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive

Cullgen (Shanghai),Inc

Phase 1/2

Beijing, Chengdu, Guangzhou, Hangzhou, Taiyuan

2023-06-20

Recruiting

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

NCT05909332Breast Cancer, Triple Negative Breast Cancer

Fudan University

Phase 3

764

Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang

2023-06-20

Recruiting

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

NCT06013618Neuroblastoma

DrugsNaxitamab·Gm-Csf·Temozolomide·Irinotecan

Sun Yat-Sen University Cancer Center

Phase 2

120

Guangzhou

2023-06-19

Recruiting

A Study on the Correlation Between Endometriosis and Intra-tissue Microbiota

NCT06266897Endometriosis

Zhujiang Hospital

Observational

500

Guangzhou

2023-06-18

Recruiting

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

NCT05837897Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

408

Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou

2023-06-16

Recruiting

DCNN Developed for Detection and Assessing the Perfusion of PTG

NCT05869058Thyroidectomy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

300

Guangzhou

2023-06-13

Recruiting

Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy

NCT05892354Locally Advanced Nasopharyngeal Carcinoma

First Affiliated Hospital of Guangxi Medical University

Not applicable

190

Fuzhou, Guangzhou, Huizhou, Guilin, Liuzhou, Nanning, Wuzhou, Yulin

2023-06-12

Not yet open

Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer

NCT05890339Stomach Neoplasms

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

216

Guangzhou

2023-06-10

Active, closed

Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors

NCT05700084Advanced Solid Tumor

DrugsUtidelone·Capecitabine

Beijing Biostar Pharmaceuticals Co., Ltd.

Phase 1/2

Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan

2023-06-09

Recruiting

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

NCT05830123Osteosarcoma, Sarcoma

DrugRis-Rez

Hansoh BioMedical R&D Company

Phase 2

170

Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

2023-06-08

Recruiting

Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.

NCT05774288Patent Foramen Ovale, Cryptogenic Stroke

Lifetech Scientific (Shenzhen) Co., Ltd.

Not applicable

244

Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming

2023-06-08

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang

2023-06-07

Recruiting

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

NCT06302062Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy

DrugsAldesleukin·Serplulimab·Cyclophosphamide

Guangzhou FineImmune Biotechnology Co., LTD.

Phase 1

Guangzhou

2023-06-06

Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3

DrugSafusidenib

Nuvation Bio Inc.

Phase 3

365

Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu

2023-06-05

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou

2023-06-05

Active, closed

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT05692492Nonalcoholic Steatohepatitis (NASH)

Guangdong Raynovent Biotech Co., Ltd

Phase 2

180

Guangzhou

2023-06-03

Recruiting

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis

NCT05882708Sepsis, Ivabradine, Hemodynamics, Heart Rate Control

DrugIvabradine

Second Affiliated Hospital of Guangzhou Medical University

Phase 4

172

Guangzhou

2023-06-01

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

NCT05862285Cancer

DrugsTiragolumab and Atezolizumab·Divarasib·Tiragolumab·Ipatasertib

Hoffmann-La Roche

Phase 3

200

Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou

2023-06-01

Active, closed

Effect of IOP Lowering on Progressive HM

NCT05850936High Myopia, Intraocular Pressure

Sun Yat-sen University

Not applicable

152

Guangzhou

2023-06-01

Active, closed

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

NCT05844150SCLC

DrugsPumitamig·Etoposide

Biotheus Inc.

Phase 2

Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan

2023-06-01

Recruiting

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

NCT05891093Breast Cancer

DrugsFluzoparib·Tamoxifen·Exemestane·Anastrozole

Fudan University

Phase 3

766

Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang

2023-06-01

Recruiting

Effects of Digital Therapeutic in Whole Process Management of Lung Cancer

NCT06230445Application of Digital Therapeutic in Lung Cancer Whole Process Management

Sun Yat-sen University

Phase 3

900

Guangzhou

2023-06-01

Recruiting

Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children

NCT05937191Idiopathic Pulmonary Hemosiderosis, Leflunomide

DrugLeflunomide

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2

Guangzhou

2023-06-01

Recruiting

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

NCT06423170Unresectable Gallbladder Cancer

DrugsCamrelizumab·Lenvatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2023-06-01

Not yet open

Donors Predisposed by Corneal Collagen Cross-linking in Deep Lamellar Keratoplasty for the Patients With Keratoconus

NCT05905978Keratoconus

Zhongshan Ophthalmic Center, Sun Yat-sen University

Not applicable

Guangzhou

2023-06

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin

2023-05-31

Recruiting

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

NCT07644897Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor

Sun Yat-sen University

Phase 2

Guangzhou, Shenzhen

2023-05-30

By invitation

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

NCT06186804cGvHD

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 2

Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou

2023-05-30

Recruiting

SG1906 for CLDN18.2-Positive Solid Tumors

NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors

Hangzhou Sumgen Biotech Co., Ltd.

Phase 1

Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou

2023-05-30

Active, closed

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

NCT05890742MSI-H

DrugSintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

453

Guangzhou

2023-05-25

Recruiting

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

NCT05859750Pancreatic Cancer

Drugs5-Fluorouracil/Leucovorin·Cadonilimab·Irinotecan·Nab-paclitaxel

Akeso

Phase 2

Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou

2023-05-25

Recruiting

Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.

NCT06746701HBV

DrugPEG IFNα-2b

Xiangya Hospital of Central South University

Observational

400

Guangzhou, Chenzhou, Hengyang

2023-05-25

Recruiting

Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis

NCT05721404Peritoneal Dialysis

DrugHypertonic Dextrose

First Affiliated Hospital, Sun Yat-Sen University

Phase 4

194

Guangzhou

2023-05-24

Recruiting

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

NCT05877872Nasopharyngeal Carcinoma, De-escaltion Therapy

Sun Yat-sen University

Phase 3

424

Guangzhou

2023-05-20

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang

2023-05-20

Recruiting

PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers

NCT05582174Upper GI Bleeding, Proton Pump Inhibitors

DrugsVonoprazan·Esomeprazole

Chinese University of Hong Kong

Phase 4

594

Guangzhou, Shenzhen, Yangjiang, Zhuhai, Hong Kong

2023-05-18

Recruiting

Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer

NCT06451211Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach

DrugsTeysuno·Tislelizumab·Capecitabine·Oxaliplatin

Sun Yat-sen University

Phase 2

Guangzhou

2023-05-17

Recruiting

Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

NCT05881265APL

DrugsChidamide·Venetoclax

Shanghai Jiao Tong University School of Medicine

Phase 2

Huai'an, Nanchang, Shanghai, Guangzhou

2023-05-15

Active, closed

Anterolateral Thigh Myofascial Fat Composite Flap for Reconstruction of Hemiglossectomy Defects in Obese Patients With Tongue Cancer

NCT07682467Tongue Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

Guangzhou

2023-05-15

Recruiting

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer

Zhejiang University

Not applicable

568

Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha

2023-05-14

Recruiting

HBsAg Declined Patients Follow-up Study

NCT05977283Hepatitis B, Hepatitis B, Chronic

Nanfang Hospital, Southern Medical University

Observational

100

Guangzhou

2023-05-11

Active, closed

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

NCT05824468Cervical Cancer, Cervical Carcinoma

DrugsZimberelimab·Lenvatinib

Sun Yat-sen University

Phase 2

Guangzhou

2023-05-10

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

NCT05862337Hepatocellular Carcinoma

DrugAnlotinib hydrochloride , Penpulimab

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

480

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning

2023-05-10

Active, closed

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

NCT05824481Endometrial Cancer, Endometrial Adenocarcinoma

DrugsCadonilimab·Lenvatinib

Sun Yat-sen University

Phase 2

Guangzhou

2023-05-08

Active, closed

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

NCT06443684Non Small Cell Lung Cancer

Shanghai Chest Hospital

Observational

305

Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai

2023-05-08

Active, closed

The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery

NCT05733208Myocardial Injury, Non-cardiac Surgery, Remote Ischemic Preconditioning

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

766

Guangzhou

2023-05-06

Active, closed

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

NCT05773820Advanced Solid Tumors

DrugWJB001

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang

2023-05-05

Active, closed

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugsARDT·[68Ga]Ga-PSMA-11·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou

2023-05-05

Recruiting

Study on Heart Failure with Preserved Ejection Fraction with Qishen Granules

NCT06377761Heart Failure with Preserved Ejection Fraction

Guangdong Provincial Hospital of Traditional Chinese Medicine

Not applicable

Guangzhou

2023-05-01

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

NCT05854849Nasopharyngeal Carcinoma

DrugsApatinib·Camrelizumab·Gemcitabine·Cisplatin

Sun Yat-sen University

Phase 3

244

Guangzhou

2023-05-01

Recruiting

Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy

NCT05845372Acute Ischemic Stroke

Nanfang Hospital, Southern Medical University

Observational

2,592

Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang

2023-05-01

Recruiting

Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma

NCT05860868Locally Advanced Nasopharyngeal Carcinoma

First Affiliated Hospital, Sun Yat-Sen University

Phase 3

474

Guangzhou

2023-05

Recruiting

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

NCT05918094Gastric Cancer

DrugSintilimab

Sun Yat-sen University

Phase 3

540

Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai

2023-04-30

Active, closed

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

NCT05869227Nasopharyngeal Carcinoma, Maintenance Therapy

XIANG YANQUN

Phase 3

166

Guangzhou

2023-04-28

Active, closed

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

NCT05799287Primary IgA Nephropathy

DrugTelitacicept

RemeGen Co., Ltd.

Phase 3

318

Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou

2023-04-28

Active, closed

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 3

Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan

2023-04-27

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai

2023-04-24

Recruiting

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

NCT05744687Locally Advanced or Metastatic Breast Cancer

DrugSPH4336

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 2/3

374

Fuzhou, Guangzhou, Guiyang, Anyang, Luoyang, Pingxiang, Changchun, Yinchuan

2023-04-24

Active, closed

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

NCT05816252Non-small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab

Klus Pharma Inc.

Phase 2

356

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2023-04-19

Recruiting

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

NCT05738694Renal Cell Carcinoma, Neoadjuvant

DrugsAxitinib·Toripalimab

ZHOU FANGJIAN

Phase 3

298

Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou

2023-04-19

Recruiting

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

NCT05103345Advanced Solid Tumor

DrugSalMet-Vec

Guangzhou Sinogen Pharmaceutical Co., Ltd

Phase 1/2

Guangzhou, Chengdu

2023-04-19

Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647Gram-negative Bacterial Infections

Pfizer

Phase 2

Beijing, Guangzhou, Shanghai

2023-04-18

Active, closed

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

NCT05707377Primary Membranous Nephropathy

DrugsTacrolimus·Zanubrutinib

BeOne Medicines

Phase 2/3

178

Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang

2023-04-17

Recruiting

The Collagen Factors of Rapid Progression of Keratoconus in Children.

NCT06722937Keratoconus

Zhongshan Ophthalmic Center, Sun Yat-sen University

Observational

160

Guangzhou

2023-04-14

Active, closed

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

NCT05645692Urothelial Cancer

DrugsTobemstomig·Tiragolumab·Atezolizumab

Hoffmann-La Roche

Phase 2

204

Beijing, Chengdu, Guangzhou, Shanghai

2023-04-13

Recruiting

Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

NCT05410925ST Elevation Myocardial Infarction

The First Affiliated Hospital with Nanjing Medical University

Phase 4

2,260

Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou

2023-04-08

Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

NCT05686642Acute Ischemic Stroke

DrugLT3001 Drug

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 2

300

Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an

2023-04-06

Active, closed

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

NCT05126719Recurrent or Metastatic Nasopharyngeal Carcinoma

DrugsBecotatug Vedotin·Docetaxel·Capecitabine

Lepu Biopharma Co., Ltd.

Phase 2

238

Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan

2023-04-06

Active, closed

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05704049Relapsed/Refractory Multiple Myeloma

DrugsMontelukast·Diphenhydramine·Acetaminophen·Isatuximab

Sanofi

Phase 2

118

Changsha, Guangzhou, Nanchang, Shenyang, Tianjin, Wuhan

2023-04-05

Recruiting

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

NCT05980702HNSCC, Oral Cancer, PD-1

DrugsCarboplatin·Pembrolizumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

192

Guangzhou

2023-04-04

Recruiting

REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry

NCT05728775Anesthesia, Surgery-Complications

DrugsRemimazolam·Propofol

Nanfang Hospital, Southern Medical University

Phase 4

7,188

Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan

2023-04-03

Active, closed

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2

999

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou

2023-04-03

Recruiting

Prolonged Progesterone to Prevent Preterm Birth From IVF - ET

NCT05787509Preterm Birth

DrugProgesterone vaginal

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 4

100

Guangzhou

2023-04-01

Not yet open

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

NCT05780294Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression

DrugsLeucogen·Lobaplatin·Adrucil

Sun Yat-sen University

Phase 3

132

Guangzhou

2023-04-01

Recruiting

Efficacy and Safety of Sodium Oligomannate in the Prevention of PSCI

NCT05545605Ischemic Stroke

DrugSodium Oligomannate

Nanfang Hospital, Southern Medical University

Not applicable

116

Guangzhou

2023-04-01

Recruiting

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

NCT05797467Colorectal Cancer, Chemotherapy Effect

DrugsCetuximab·Bevacizumab

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 3

366

Guangzhou

2023-04-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=5

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,345 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,977 of the 3,345 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 479 have not yet opened recruitment, 820 are active but closed to new participants, and 69 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.